• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UCB begins C-EARLY study for rheumatoid arthiritis

UCB begins C-EARLY study for rheumatoid arthiritis

February 27, 2012
CenterWatch Staff

Brussels-based UCB has initiated C-EARLY, a phase III study to evaluate the efficacy and safety of Cimzia (certolizumab pegol) in combination with methotrexate (MTX) for inducing and sustaining clinical response in adults with rheumatoid arthritis (RA) not previously treated with disease-modifying antirheumatic drugs (DMARDs).

The study also aims to assess whether the frequency of certolizumab pegol administration can be reduced after sustained low disease activity has been achieved. C-EARLY will evaluate patients in the early stage of their disease—less than one year since diagnosis.

"There is growing evidence to support the value of detecting and treating rheumatoid arthritis patients as soon as possible after the onset of disease in order to prevent disease progression. By rapidly achieving the target of sustained remission early in the course of RA, drug-free remission could become an achievable goal," said Professor Paul Emery, professor of rheumatology, University of Leeds, U.K.

C-EARLY is a phase III, multi-center, randomized, double-blind, placebo-controlled study that will randomize patients diagnosed with early, progressive, active, moderate to severe RA to certolizumab pegol plus methotrexate (MTX) or placebo plus MTX for 52 weeks. Patients who achieve sustained remission with certolizumab pegol at week 52 will be re-randomized to varying reduced doses of certolizumab or withdrawn from certolizumab for a further 52 weeks.

The co-primary efficacy variables are the proportion of patients reaching sustained remission at week 52, and the proportion of patients who maintain low disease activity between week 52 and week 104. The study aims to enroll approximately 800 adult patients in the U.S., Canada and Europe who are naive to DMARDs.  Headline results for the study are expected in 2016.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing